PinnyPeptide

PE22-28 vs Pinealon

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

PE22-28

Cognitive

Fast-acting antidepressant peptide acting via TREK-1 channel inhibition.

Peptide B

Pinealon

Cognitive

Neuroprotective tripeptide bioregulator that penetrates the nuclear membrane to directly regulate gene expression in brain tissue.

Typical vial

5 mg

Typical dose

50-200 mcg

Half-life

Hours; precise value species-dependent

FDA status

Not FDA approved.

Typical vial

20 mg

Typical dose

100-500 mcg

Half-life

~1-2 hours (estimated; formal pharmacokinetic data in humans is not published — biological effects on gene expression persist beyond plasma clearance)

FDA status

Not FDA approved. No IND or NDA has been submitted to the FD…

PE22-28 effects

  • Selective TREK-1 potassium channel inhibition
  • Fast-onset antidepressant-like effects in rodent models
  • Increased serotonergic neuron firing in dorsal raphe
  • Enhanced BDNF / TrkB signaling downstream
  • Anti-anxiety effects in some assays

Pinealon effects

  • Suppresses reactive oxygen species (ROS) accumulation in neuronal cells, reducing oxidative stress-driven cell death
  • Preserves dendritic spine morphology in models of Alzheimer's and Huntington's disease, protecting synaptic integrity
  • Modulates gene expression via direct nuclear membrane penetration, regulating genes involved in neuronal survival (SOD2, GPX1, CASP3, APOE)
  • Supports serotonin biosynthesis by promoting 5-tryptophan hydroxylase expression, with potential mood-regulatory effects
  • Reduces apoptotic signaling in neurons by downregulating pro-apoptotic proteins including caspase-3
  • Reported improvement in memory, cognitive performance, and reduced headache duration in patients with traumatic brain injury sequelae

PE22-28 side effects

  • Essentially uncharacterized in humans
  • Theoretical: TREK-1 inhibition off-target in heart, immune cells
  • Subjective reports of mood activation, occasional anxiety
  • Injection-site reactions
  • Sleep disturbance with late-day dosing

Pinealon side effects

  • Injection site reactions: mild redness, itching, or transient swelling at subcutaneous injection site
  • Headache or mild dizziness, particularly early in a dosing cycle
  • Vivid dreams or mild sleep disturbance if administered late in the day (likely related to CNS activity)
  • Gastrointestinal discomfort (more commonly reported with oral capsule form)
  • Rare: transient mild anxiety or fatigue; allergic hypersensitivity reactions are possible but not well-documented in the literature

PE22-28 dosing ranges

Antidepressant research (preclinical)

100-500 mcg/kg · Daily SubQ or IP · Per protocol

Self-experimentation (no clinical guidance)

50-200 mcg · Once or twice daily · 2-4 weeks per cycle

Pinealon dosing ranges

Cognitive support and neuroprotection (subcutaneous)

100-500 mcg · Once daily · 10-20 days per cycle, repeated 2-4 times per year

Traumatic brain injury sequelae / cerebral asthenia (oral, clinical study protocol)

0.2 mg (200 mcg) twice daily · Twice daily · 20-30 days

General anti-aging and brain longevity (oral supplement)

10-20 mg per day (1-2 capsules of 10 mg each) · Once or twice daily, 30 minutes before meals · 1 month on, then reassess

Full PE22-28 guide → Full Pinealon guide →

PE22-28 vs Pinealon — common questions

What is the difference between PE22-28 and Pinealon?

PE22-28: Fast-acting antidepressant peptide acting via TREK-1 channel inhibition. Typical dose 50-200 mcg. Pinealon: Neuroprotective tripeptide bioregulator that penetrates the nuclear membrane to directly regulate gene expression in brain tissue. Typical dose 100-500 mcg. Both fall under the Cognitive category.

Can you stack PE22-28 and Pinealon?

Stacking PE22-28 with Pinealon is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, PE22-28 or Pinealon?

PE22-28 is typically dosed: Daily SubQ or IP for Antidepressant research (preclinical); Once or twice daily for Self-experimentation (no clinical guidance). Pinealon is typically dosed: Once daily for Cognitive support and neuroprotection (subcutaneous); Twice daily for Traumatic brain injury sequelae / cerebral asthenia (oral, clinical study protocol); Once or twice daily, 30 minutes before meals for General anti-aging and brain longevity (oral supplement).

Are PE22-28 and Pinealon FDA approved?

PE22-28: Not FDA approved. Pinealon: Not FDA approved. No IND or NDA has been submitted to the FDA. Classified as a research chemical in the United States.

Related peptide comparisons

adamax vs pe22-28colivelin vs pe22-28dihexa vs pe22-28dnsp-11 vs pe22-28p21 vs pe22-28acth-1-39 vs pinealon

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free